BioSpace

Strong immunology and neuroscience sales fueled AbbVie’s latest quarterly beat as the pharma’s stock continues to hit all-time highs. hubs.li/Q04CVJT-0

“You don’t spend one and a half billion dollars without creating jobs,” AstraZeneca CEO Pascal Soriot said as the pharma announced a new cost savings program alongside third quarter earnings. hubs.li/Q04CVJSb0

Focused on ensuring growth beyond Dupixent, Sanofi wants to acquire derisked assets that may benefit from the French pharma’s commercial capabilities, executives said on Friday as they reported third-quarter earnings. hubs.li/Q04CVJ8Z0

Acumen will implement cash-saving strategies and assess its options after sabirnetug failed to beat placebo, leaving the biotech without a clinical program. hubs.li/Q04CStW80

Alnylam shares dropped by a quarter on Thursday, with analysts suggesting the decline puts the RNAi specialist within range for a takeout. hubs.li/Q04CSqV80

Early-stage clinical data from our company and others point to the Wnt/β-catenin pathway as a new avenue for targeting multiple cancer types. hubs.li/Q04CSgkm0

Setara Biosciences has formed around a handful of assets from Actio Biosciences, which was acquired by Jazz Pharmaceuticals earlier this year. hubs.li/Q04CSgcd0

After Sanofi paid $600 million in cash to acquire Dren Bio’s bispecific last year, the biotech has secured a hefty financing to fund late-stage development and commercial preparations for its lead asset. hubs.li/Q04CSg1Z0

With the commercial business performing so well, Eli Lilly is eyeing earlier business development bets to build out a longer-term pipeline. hubs.li/Q04CSfPt0

On its Q3 earnings call, Merck executives touted recent pipeline wins alongside a strong performance for subcutaneous Keytruda and pulmonary arterial hypertension drug Winrevair that drove the pharma’s overall sales expectations to surpass expectations. hubs.li/Q04CSfrk0

In addition to canning an Orum-acquired blood cancer candidate last month, Bristol Myers Squibb cut a Prothena-partnered neuro asset in the third quarter. But with sales climbing 7%, the Big Pharma raised its full-year revenue forecast. hubs.li/Q04CSfcc0

As part of a strategic reorganization announced Wednesday and intended in part to “streamline the organization,” LENZ Therapeutics will decrease headcount by about 75% to around 40 full-time employees, according to an SEC filing from the same day. hubs.li/Q04CLGQf0

Ono Pharma’s ONO-1110 failed five Phase 2 trials, leading to the discontinuation of development in depression and social anxiety. Work will continue for three pain indications. hubs.li/Q04CLFxV0

Eli Lilly’s shares rose 4% in early morning trading after reporting revenue of $24.4 billion, well past consensus estimates. hubs.li/Q04CLfZJ0

Looking for a biopharma job in New York? Jobs on BioSpace have soared year over year and month over month. hubs.li/Q04CL32b0

Under the interim policy, officials do not intend to take action against sites that produce the peptides. hubs.li/Q04CL2s-0

On Denatured, Jerome Barley, commercial director at Avion Medical, and Ryan Klein, VP of business development, US and APAC at Resolian, discuss Australia’s trial appeal and how its speed, regulatory clarity, and tax incentives may expand its biotech role. hubs.li/Q04CL2sw0

As companies invest billions of dollars to reshore manufacturing, 10 biotech and pharma businesses are reportedly trimming staff at manufacturing locations in 2026 or the coming years, with BioNTech having the deepest cuts. hubs.li/Q04CL0W10

Analysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans. hubs.li/Q04CL0nL0

Biogen is growing as planned, with marketed products generating more revenue and multiple late-stage readouts expected over the next year. Building out an early-stage pipeline would be a bonus, CEO Chris Viehbacher said on a Q3 earnings call Wednesday. hubs.li/Q04CL0bF0